MedImmune

MedImmune, Inc. has made several new senior appointments across the organization. Alexander A. Zukiwski, M.D., senior vice president, clinical research; Timothy J. Hahn, Ph.D., vice president, antibody manufacturing; and Timothy J. Maines, vice president, corporate quality assurance have recently joined the company. New executive promotions include Max Donley, vice president, human resources; Jonathan Klein-Evans, J.D., vice president, intellectual property; Timothy Pearson, vice president and chief financial officer; and Paul Williams, vice president, sales operations.

“As MedImmune transitions into its new role as the global biologics unit of AstraZeneca, it is imperative to strengthen the company’s leadership platform across all facets of our business. Alex, Tim Hahn and Tim Maines add an additional depth of expertise in the areas of clinical research, antibody manufacturing, and quality assurance, respectively, which are each critical to our ability to deliver new drugs to patients in need,” said David M. Mott, chief executive officer and president. “The new vice presidential appointments of Max, Jonathan, Tim Pearson and Paul foster MedImmune’s ability to continue to recruit and grow talent, protect our intellectual properties, manage our financial reporting obligations to our parent company AstraZeneca and serve our customers to the highest possible standards.”

Dr. Zukiwski will be responsible for the company’s strategy for clinical trials of its drug candidates. Prior to joining the company, he held several roles of increasing responsibility in support of Johnson & Johnson’s (J&J) medical affairs and clinical development functions at Johnson & Johnson Pharmaceutical Research & Development, LLC (J&JPRD); Centocor R&D; and Ortho Biotech, including therapeutic area head for oncology and acting head of oncology R&D. Most recently he served as vice president, head of clinical oncology, responsible for strategic oversight and portfolio management of therapeutic oncology, hematology and supportive care clinical development programs for J&JPRD and Centocor’s oncology development group. Before joining J&J, Dr. Zukiwski served in clinical oncology positions at pharmaceutical companies such as Hoffmann-LaRoche, Glaxo Wellcome and Rhone-Poulenc Rorer.

Dr. Hahn will be responsible for the antibody manufacturing strategy, including overall operations at MedImmune’s cell culture manufacturing facility currently under construction in Frederick, MD, as well as existing sites in Frederick and Nijmegen, Netherlands. He has more than 15 years experience in cell culture and live virus vaccine manufacturing with Merck & Co.

Mr. Maines will be responsible for quality systems to improve the infrastructure of quality assurance operations in support of future growth, for ensuring the company’s products meet corporate and government standards and that quality assurance activities comply with applicable regulations, and for providing enhanced expertise and guidance in interpreting government regulations and guidelines. He joins the company with more than 20 years of pharmaceutical, medical device and biologics industry experience as a microbiologist and quality professional. He most recently held positions at GTC Biotherapeutics, where he served as vice president of corporate quality, and Stryker Corp., where he was director of quality assurance.

Mr. Donley will be responsible for providing business-integrated leadership and delivering professional tools, programs and services to optimize the company’s human capital investments through the HR function across all sites to drive business results. Prior to joining the company in 2000 as a senior manager, he led field HR and development at Bed Bath & Beyond.

Mr. Klein-Evans will be responsible for overseeing all intellectual property issues for the company. He has 15 years of experience working on all aspects of patent law, including prosecution, litigation, opinions, interferences, oppositions and licensing. He joined the company in 2002 as director, intellectual property. Previously, he was an in-house patent attorney at Human Genome Sciences, Inc. (HGS). Prior to that, he worked for the law firm of Pennie & Edmonds, LLP.

Mr. Pearson will be responsible for overseeing the company’s financial and accounting obligations. Since joining the company in 1998, Mr. Pearson has raised more than $1.6 billion in debt throughout the course of his tenure, and served as corporate secretary from 2000-2004. Previously, he worked at Integrated Health Services, Inc., most recently as assistant treasurer; at CIGNA Insurance as treasury manager; and at First National Bank of Maryland as a commercial lending officer.

Mr. Paul Williams will be responsible for overseeing market research and marketing operations as well as for managing core sales operations competencies. Prior to joining the company he was a senior director at Centocor, Inc., guiding trade sales, customer supply chain and channel strategy.